Drug
HSK39297 clinical trials
Also written HSK39297.
Keep track of what changes. Save the HSK39297 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Studies
Open first, then newest update. How each study uses HSK39297 is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA NephropathyRecruitingPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT07616700Written as HSK39297 200mgQD
- Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANRecruitingPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT07390123Written as HSK39297
- Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LNRecruitingPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT07363460Written as HSK39297 200mgQD
- Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic ImpairmentRecruitingPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT07152288Written as HSK39297 tablets
- Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal HemoglobinuriaRecruitingPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT06745622Written as HSK39297 tablets
- Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANCompletedPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT06670352Written as HSK39297 50mgBID
- Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With AnemiaCompletedPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT07052838Written as HSK39297 tablets
- A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor TherapyCompletedPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT06799546Written as HSK39297 tablets
- A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）CompletedPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT06561841Written as HSK39297
- A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy SubjectsCompletedPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT06350279Written as HSK39297